Standalone Q2 net profit nearly doubles; H1 net profit more than doubles

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

ACUTAAS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+6.1%Reaction day

₹1560.00

prior close

₹1573.70

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.2%+6.4% vs market

Pharmaceuticals peers, median of 153sector-0.1%+6.3% vs sector

On the reaction day the stock moved 6.4 pts more than Nifty Smallcap 250 and 6.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+1.7

15m

+0.9

30m

+2.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+6.1-0.2+6.4-0.1+6.3

Next day

+13.7+0.3+13.4+0.0+13.7

+14.4+1.0+13.4+0.4+14.0

+11.9+0.7+11.2+0.0+11.9

+7.9+0.6+7.3+0.1+7.8

+10.7+1.2+9.5-0.1+10.8

+8.4+1.8+6.7+0.0+8.4

15d

+11.8-0.7+12.5-1.7+13.5

+9.8+0.5+9.3-1.0+10.8

+6.4-5.3+11.7-5.2+11.7

+7.7-6.4+14.1-9.3+16.9

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 153Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Unaudited Q2 and H1 results ending September 30, 2025 were approved. Standalone Q2 revenue rose 25.3% to Rs 30,519.34 lakh and net profit rose 93.5% to Rs 7,289.36 lakh. Standalone H1 revenue rose 23.4% to Rs 51,164.30 lakh and net profit rose 128.7% to Rs 11,753.78 lakh. Consolidated H1: revenue Rs 51,343.30 lakh, net profit Rs 11,722.64 lakh. Group operating cash flow was positive at Rs 13,650.49 lakh. The limited review reported no issues.

Likely market impact

Strong revenue growth, faster profit growth, positive cash flow and no review concerns should support sentiment, though figures are unaudited.